Evidence map›Paper›PMID 35900151›Full record

ArticleBioinformatics (Oxford, England)2022

SECEDO: SNV-based subclone detection using ultra-low coverage single-cell DNA sequencing.

Hana Rozhoňová, Daniel Danciu, Stefan Stark, Gunnar Rätsch, André Kahles, Kjong-Van Lehmann

Open access · hybridAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Hana RozhoňováBiomedical Informatics Group, Department of Computer Science, ETH Zurich, Zurich, Switzerland.
Daniel DanciuBiomedical Informatics Group, Department of Computer Science, ETH Zurich, Zurich, Switzerland.
Stefan StarkBiomedical Informatics Group, Department of Computer Science, ETH Zurich, Zurich, Switzerland.ORCID 0000-0003-2478-9512
Gunnar RätschBiomedical Informatics Group, Department of Computer Science, ETH Zurich, Zurich, Switzerland.ORCID 0000-0001-5486-8532
André KahlesBiomedical Informatics Group, Department of Computer Science, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-3411-0692
Kjong-Van LehmannBiomedical Informatics Group, Department of Computer Science, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-1936-298X
SIB Swiss Institute of Bioinformatics · CHETH Zurich · CH

Funding

ETH
6 · The paper itself

Abstract

motivationSeveral recently developed single-cell DNA sequencing technologies enable whole-genome sequencing of thousands of cells. However, the ultra-low coverage of the sequenced data (<0.05× per cell) mostly limits their usage to the identification of copy number alterations in multi-megabase segments. Many tumors are not copy number-driven, and thus single-nucleotide variant (SNV)-based subclone detection may contribute to a more comprehensive view on intra-tumor heterogeneity. Due to the low coverage of the data, the identification of SNVs is only possible when superimposing the sequenced genomes of hundreds of genetically similar cells. Thus, we have developed a new approach to efficiently cluster tumor cells based on a Bayesian filtering approach of relevant loci and exploiting read overlap and phasing.

resultsWe developed Single Cell Data Tumor Clusterer (SECEDO, lat. 'to separate'), a new method to cluster tumor cells based solely on SNVs, inferred on ultra-low coverage single-cell DNA sequencing data. We applied SECEDO to a synthetic dataset simulating 7250 cells and eight tumor subclones from a single patient and were able to accurately reconstruct the clonal composition, detecting 92.11% of the somatic SNVs, with the smallest clusters representing only 6.9% of the total population. When applied to five real single-cell sequencing datasets from a breast cancer patient, each consisting of ≈2000 cells, SECEDO was able to recover the major clonal composition in each dataset at the original coverage of 0.03×, achieving an Adjusted Rand Index (ARI) score of ≈0.6. The current state-of-the-art SNV-based clustering method achieved an ARI score of ≈0, even after merging cells to create higher coverage data (factor 10 increase), and was only able to match SECEDOs performance when pooling data from all five datasets, in addition to artificially increasing the sequencing coverage by a factor of 7. Variant calling on the resulting clusters recovered more than twice as many SNVs as would have been detected if calling on all cells together. Further, the allelic ratio of the called SNVs on each subcluster was more than double relative to the allelic ratio of the SNVs called without clustering, thus demonstrating that calling variants on subclones, in addition to both increasing sensitivity of SNV detection and attaching SNVs to subclones, significantly increases the confidence of the called variants. AVAILABILITY AND IMPLEMENTATION: SECEDO is implemented in C++ and is publicly available at https://github.com/ratschlab/secedo. Instructions to download the data and the evaluation code to reproduce the findings in this paper are available at: https://github.com/ratschlab/secedo-evaluation. The code and data of the submitted version are archived at: https://doi.org/10.5281/zenodo.6516955. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

High-Throughput Nucleotide SequencingNeoplasmsBase SequenceBayes TheoremGenomeHumansPolymorphism, Single NucleotideSequence Analysis, DNA

Identifiers

PMID35900151
PMCPMC9477524
OpenAlexW4288442931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.